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Abstract
Background: The use of information technology (IT) is now the preferred method of capturing and storing clinical
research data. The Treatment In Morning versus Evening (TIME) study predominantly uses electronic data capture
and IT to compare morning dosing of hypertensive medication against evening dosing. Registration, consent,
participant demographics and follow-up data are all captured via the study website. The aim of this article is to
assess the success of the TIME methodology compared with similar studies.
Methods: To assess the TIME study, published literature on similar clinical trials was reviewed and compared against
TIME recruitment, follow-up and email interaction data.
Results: The TIME website registered 31,695 individuals, 21,116 of whom were randomised. Recruitment cost per
randomised participant varied by strategy: £17.40 by GP practice, £3.08 by UK Biobank and £58.82 for GoShare.
Twelve-month follow-up retention rates were 96%. A total of 1089 participants have withdrawn from their assigned time
of dosing, 2% of whom have declined follow-up by record linkage or further contact. When the TIME data are compared
with similar study data, study recruitment is very successful. However, TIME suffers difficulties with participant follow-up
and withdrawal rates similar to those of conventional studies.
Conclusions: The TIME study has been successful in recruitment. Follow-up, retention rates and withdrawal rates are all
acceptable, but ongoing work is required to ensure participants remain engaged with the study. Various recruitment
strategies are necessary, and all viable options should be encouraged to maintain participant engagement throughout
the life of studies using IT.
Background
Randomised controlled trials are the most reliable
method of evaluating the efficacy or safety of a drug
therapy [1]. Research and clinical studies have evolved to
the use of the newest technologies and methodologies,
with electronic data capture (EDC) now being common-
place and preferable [2–5]. In parallel, email use has
quickly developed to replace face-to-face consultations
[6–8] and study screening visits [9]. Email has also been
shown to be an effective intervention technique for
changing participant behaviour [10–13] and an effective
method of recruitment to clinical trials [14]. Further
research is needed to understand how studies that use
information technology (IT) compare with similar
conventional studies in terms of efficiency and validity.
The Treatment In Morning versus Evening (TIME)
study [15] is a British Heart Foundation (BHF)-funded
clinical study comparing morning dosing of usual hyper-
tensive medication with evening dosing to determine if
one is better than the other in terms of cardiovascular
outcomes. The study is conducted predominantly using
an online website and is an example of a study where IT
and EDC are used to maximise study proficiency and
minimise costs.
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The TIME study uses a novel online methodology and
IT to recruit participants, obtain consent, collect base-
line data and follow participants. Interested individuals
self-enrol on the study website (www.timestudy.co.uk)
with a password of their choice and their email address.
Those who choose to take part then consent and enter
demographic data via the secure website, are followed at
routine intervals via automated emails, and are asked to
enter patient-reported outcomes (PROs) online. The
study has surpassed recruitment expectations, with over
21,000 participants randomised over a 2-year period.
However, it is unclear how successful the study method-
ology will be compared with conventional data collection
methods. The purpose of this research paper is to evalu-
ate the TIME study and its online methodology in each
of the following areas:
 Recruitment
 Follow-up, retention and adherence
 Email and telephone interactions
Methods
The TIME study recruited participants using various re-
cruitment strategies: radio advertising, posters in general
practitioners’ (GPs’) practices, newspapers, direct email
and letters from GPs, hospital clinics, pharmacies, and
research study databases of individuals who had agreed
to be contacted about research. Interested individuals
were invited to register on the study website, to submit
how they heard about the study, indicate their consent
to participate, and enter the demographic information
and medical history data necessary for the study (Fig. 1).
Participants were also asked to provide contact informa-
tion for a nominated surrogate who could be contacted
in the event that email contact with the participant was
lost. A copy of the participant’s consent form was sent to
the participant along with an email confirming their allo-
cated time to take their hypertensive medication (morning
or evening). Follow-up emails are sent on a 3-monthly
basis to assess adherence to allocated dosing time and to
identify any potentially related adverse events that the par-
ticipant has experienced. Owing to the potentially poor
quality of data from PROs [16], record linkage to nation-
ally held hospitalisation and mortality data is used to iden-
tify potential study endpoint events. Participants are able
to contact study staff at any point during the study using a
Freephone number and by email or post. Data on study
contact by participants were collected during active
recruitment by GP practices and after recruitment by GP
practices had ceased, in order to assess resource use dur-
ing the recruitment phase of the study.
To evaluate the study methodology, a review of pub-
lished literature was conducted. The PubMed library was
searched using general search terms with the aim of
identifying average cost per randomised study participant,
retention rates, rates of loss to follow-up, withdrawal rates,
and email use and interactions in clinical trials. The
remainder of this article compares the TIME study data
with the study data identified from the literature review,
highlighting the studies’ successes and limitations as well
as what should be investigated in further research.
Fig. 1 Flow diagram for Treatment In Morning versus Evening (TIME)
study website. BP Blood pressure, CV Cardiovascular
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Results
The TIME study began as a feasibility pilot [17] in De-
cember 2011. On the basis of data derived from the pilot
study, the BHF funded TIME to recruit 10,269 partici-
pants into a formal study. To accommodate the decreas-
ing cardiovascular event rate observed in other studies
[18], the recruitment target was increased to at least
21,000. It was believed that doubling the recruitment
target would ensure achieving the necessary number of
events needed to power the study within a reasonable
time frame. This increase was made possible by the
success of the various recruitment strategies used.
Recruitment
Active recruitment into the study closed in August 2016,
and the TIME study website closed to new registrations
at the end of March 2017. The majority of participants
were randomised between March 2015 and July 2016
(20,132 [95%]), largely due to the work of clinical
research networks and GP practices in sending letters to
patients with hypertension. During this period, the most
successful month was April 2016, in which 1989 partici-
pants were randomised. The least successful month,
March 2015, saw 421 participants randomised. On aver-
age, TIME randomised 1184 participants per month over
this period. Overall, between the pilot start date, Decem-
ber 2011, and the registration closure date, August 2017,
31,695 individuals registered with the TIME study web-
site. Of these, 23,617 (72%) met the eligibility criteria
(≥18 years old, not currently in a study, having a valid
email address, and receiving one or more antihyperten-
sive drugs) and went on to complete the online consent
process. A total of 2502 (8%) individuals consented, and
were eligible, but did not complete the enrolment
process and go on to be randomised into the study. A
total of 21,116 (67%) individuals went on to be rando-
mised into the study and were allocated a time of dosing
for their antihypertensive medication (Fig. 2).
The TIME study was advertised to potential partici-
pants using various strategies. One month after the pilot
study began recruitment, data were captured on how
registered visitors to the website had come to hear about
the study. Each recruitment strategy varied in cost and
effectiveness; this is detailed in Table 1. In an effort to
expedite recruitment, UK Biobank [19] and GoShare
[20] were recruited to assist in contacting individuals
and making them aware of the study. UK Biobank and
GoShare are both health registries whose aim is to im-
prove the prevention, diagnosis and treatment of a wide
range of serious and life-threatening illnesses. These data-
bases contain details on individuals who have voluntarily
registered, given detailed information about themselves
and agreed to have their health status tracked. Over many
years these will build into powerful resources to help
scientists discover why some people develop particular
diseases and others do not. UK Biobank sent 79,628
emails to participants with hypertension in their database
at a total cost of £10,000, or £3.08 per randomised partici-
pant (recruitment rate of 4.1%). GoShare sent 12,931
emails to patients with hypertension at a cost of £2000, or
£58.82 per randomised participant. The largest number of
TIME participants were recruited from GP practices that
had sent individual letters inviting patients to register on
the study website. GP practices sent 594,289 letters to
patients known to be on at least one antihypertensive
medication, using the Docmail [21] mailing service, at a
cost of £277,140, or £17.40 per randomised participant
(recruitment rate of 2.7%). Posters displayed in primary
and secondary care settings advertising the study were not
as successful [22], initially costing £315 per randomised
Fig. 2 Treatment In Morning versus Evening (TIME) study recruitment of randomised participants from 2015 to 2017 (n = 21,116)
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participant. This cost has been reduced to £78 per rando-
mised participant as a result of the work of the research
networks engaging with practices and distributing
additional posters during the recruitment period. Other
recruitment strategies used were either free or conducted
and funded by supporting bodies, including the BHF, the
British and Irish Hypertension Society, the National Insti-
tute for Health Research (NIHR) Clinical Research Net-
work, and the Scottish Primary Care Research Network.
Recruitment review
The literature identified suggests that researchers should
use various methods to meet recruitment targets [23,
24]. Over the past decade participant recruitment in
clinical trials has not increased, with only 3% of eligible
participants agreeing to take part in clinical research
[25]. The response rate to TIME study invitations was
similar (4.1% for Biobank and 2.7% for GP letters), but
the low-cost recruitment strategies implemented allowed
for researchers to double the study population to 21,000
from the initial 10,269, despite research governance de-
lays [26]. Involvement of the NIHR Clinical Research
Network and the Scottish Primary Care Research Net-
work was invaluable in achieving this.
Trial recruitment costs are reported to vary greatly be-
tween studies [27, 28]. Online recruitment has consist-
ently been successful at recruiting more participants in
terms of raw numbers and recruiting participants from
hard-to-reach populations, and it is more cost-effective
than offline methods [29]. However, the technology does
bring new challenges. It has been suggested that online
recruitment could hinder the identification of well-defined
populations and trials reporting PROs have been met with
some scepticism about reliability [30]. The TIME study
researchers aimed to mitigate this by using PROs to aug-
ment a primary study endpoint determined by record link-
age to hospitalisations and deaths. To ensure that online
studies are generalisable to the target population, it will be
important to assess whether participants recruited online
are representative of the target population.
Direct contact with study staff is still preferable for some
participants [31], and barriers other than household inter-
net access still exist that need to be considered during the
recruitment process [32]. During the TIME study recruit-
ment, 8074 people registered but failed to consent or were
ineligible, and 2502 individuals failed to complete the
enrolment process. The reasons for this remain unknown,
and owing to ethical restrictions we are unable to collect
these data. Participants clearly responded positively to let-
ters from their own GPs’ practices; this appears consistent
with similar studies in the United Kingdom using equiva-
lent recruitment strategies [33].
Follow-up, retention and adherence
PROs are elicited in the TIME study by follow-up emails
sent to the participants on a 3-monthly basis. Partici-
pants are asked to click on a link within each follow-up
email, which automatically takes them to the study web-
site, where they are asked to submit their data. As of
March 2017, there were 96,418 completed follow-ups
logged on the database. There were a mean of four
follow-ups per randomised participant (median of five).
Table 1 Treatment In Morning versus Evening (TIME) study registration statistics: how participants heard about the study and cost, if
known
Recruitment method Registrations (n = 30,775) (%) Randomised (n = 20,914) (%) Cost per randomised participant (if known)
Radio 70 (< 1) 62 (< 1)
Friends/relatives 102 (< 1) 65 (< 1)
Web search 96 (< 1) 53 (< 1)
From GP 22,675 (74) 15,932 (76) £17.40
MEMO website 104 (< 1) 44 (< 1)
Practice poster 261 (< 1) 161 (< 1) £78.00
TIME video (YouTube) 14(< 1) 6 (< 1)
Medscape 8 (< 1) 3 (< 1)
BHF Heart Matters 332 (1) 249 (1)
Pharmacy 27 (< 1) 16 (< 1)
Newspaper 17 (< 1) 8 (< 1)
Hospital or clinic 939 (3) 615 (3)
Biobank 5358 (17) 3242 (16) £3.08
GoShare 55 (< 1) 34 (< 1) £58.82
Other 717 (2) 424 (2)
BHF British Heart Foundation, GP General practitioner
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The most follow-ups reported by a single participant
were 25. Approximately 96% (19,882) of all live study
participants (not withdrawn or deceased) had follow-up
information available from within the last 12 months,
and efforts are ongoing to contact those participants for
whom follow-up data are overdue.
If participants fail to respond to their first follow-up
email, they are sent a reminder follow-up email after
14 days. If, after a further 14 days, they fail to respond to
the second follow-up email, then an email is sent to the
participant’s surrogate whom they nominated during en-
rolment, asking after the well-being of the participant
and for any reasons the participant may not have replied
to study emails. A total of 6158 surrogate emails had
been sent between March 2012 and March 2017, result-
ing in 669 (11%) responses from participant surrogates.
In an effort to capture whether participants had read
and understood their allocated time of dosing email, a
link was added to the allocation email. This link asked
the participant to click it if they had understood and
acknowledged the time they had been requested to take
their hypertensive medication. This link was incorpo-
rated into the allocation email in October 2015, and
11,483 (54%) of randomised participants received the
email link. Of these, 7949 (69%) participants clicked the
link indicating they had received and understood their
allocation email. A total of 3471 (16%) participants have
indicated that they have not adhered to their allocated
time of dosing during at least one 3-month follow-up
period in the study. A total of 1089 people have formally
withdrawn from email follow-up since the pilot began in
2011 (11,070,614 patient-days), but only 388 (2%) indi-
cated refusal to be followed by record linkage.
Follow-up, retention and adherence review
Whilst there are studies conducted on improving partici-
pant adherence [34–37], adherence to allocated treat-
ment during clinical studies is under-reported in the
literature. Drop-out rates and loss to follow-up are more
widely documented. Reported drop-out rates for studies
vary greatly, from 0% to 45.5% [38, 39]. Reasons for
withdrawal are occasionally reported under typically
generic categories, with ‘patient decision’ and ‘adverse
event’ being the most frequently reported [40]. A sug-
gested general ‘rule of thumb’ is that < 5% drop-out leads
to little bias, whereas > 20% poses a serious threat to val-
idity [41]. Currently 5% of participants have withdrawn
from TIME. Participants who wish to withdraw from
studies owing to being allocated to their unfavoured
treatment arm is a concern and indicates a disappointing
lack of understanding of the clinical research process,
despite extensive pre-consent written information. Such
disappointment is known to be common in clinical stud-
ies where participants had hoped to be allocated to an
active treatment group. Consent information is of high
importance because those who are very disappointed
often claim they did not receive understandable informa-
tion [42]. In addressing specific patient concerns, atten-
tion to a patient’s emotional status and expectations of
trial participation have been found to be associated with
better adherence [43]. Researchers in a study of cardio-
vascular events in diabetes (ASCEND) [33] implemented
a run-in period before participants were randomised to
ascertain protocol compliance. This process helped
alleviate the drop-out rate by identifying non-compliant
participants early in the study process and before ran-
domisation took place. There are drawbacks with such a
run-in period: increase in study costs, prolongation of
the study and underestimation of adverse reactions. How-
ever, given the detrimental impact of study withdrawals, a
run-in period, which does not exclude participants for rea-
sons other than treatment arm non-compliance, may be
worth further consideration for clinical studies.
Whilst online recruitment is effective, remote follow-
up strategies do not reduce the loss to follow-up [44].
There are many reasons for loss to follow-up: Partici-
pants may move, deaths may be unreported, or the par-
ticipant may decide to no longer take part without
informing study staff. In some instances the participant
may simply no longer comply with the study protocol
and not explicitly withdraw consent. There continues to
be confusion regarding when a participant is formally
withdrawn [45], but if the withdrawal of consent is mis-
interpreted by the study investigator, valuable data may
be lost. The most common reasons cited for continuing
participation in research are 24-h access to nurses, bet-
ter treatment of care and a desire to help others [46, 47].
Retention in a clinical trial appears to depend on expert
medical care, supportive staff-participant relationships,
involvement with clinically and scientifically meaningful
research, and management of participant expectations
[48]. The extent to which these issues impact the results
of TIME remains to be seen.
Email and telephone interactions
Individuals interested in taking part in the TIME study
were able to contact study staff by a Freephone number,
by email or by letter. To better understand the resource
allocation required for a study using this methodology,
we logged all telephone and email contacts for 1 month
whilst recruitment was actively being pursued. During a
4-week period in June 2016, 3005 people registered with
the study website. Of those, 1860 (62%) went on to con-
sent, complete enrolment and be randomised to a time
of dosing. There were 1090 queries to the department
about the study during this time: 457 (42%) telephone
calls, 522 (48%) emails, and 108 (10%) queries submitted
using an online support tool on the study website. There
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were three additional queries where the method of con-
tact was not recorded. The content of the queries varied:
116 (11%) were IT problems, 199 (18%) were clinically
related questions, 701 (64%) were administrative or gen-
eral enquiries, 64 (6%) were queries about withdrawing
from the study, and 10 were complaints about study
processes (Table 2).
This exercise was repeated in November 2016, when
active recruitment had ceased. During this month, 61 in-
dividuals registered with the study website, 21 of whom
went on to be randomised. There were 401 queries to
the department: 300 (75%) by email, 54 (13%) by phone
and 57 (14%) via the online support tool. Of these, there
were 8 (2%) IT issues, 48 (12%) clinical queries, 302
(75%) administrative or general enquiries, 42 (10%) quer-
ies on how to withdraw and 1 complaint (Table 3).
Email and telephone interactions review
The literature on email use in clinical studies is positive,
with reports of it being used effectively in research [6–14].
The amount of resource that email and telephone en-
quiries required was large during the TIME recruitment
phase. This is one area that should not be underestimated
by researchers when planning study resources. The emails
themselves became a key form of data. It became clear
during the study that they potentially provide richly con-
textual prospective records, and this remains an area that
is under-researched. Emails often recorded the context of
volunteering and the motivations and priorities of volun-
teers. The volume of both emails and telephone calls
highlighted the ‘invisible work’ of research staff during
what are typically considered to be standard administra-
tive tasks [49]. One area of concern highlighted by the lit-
erature was the lack of a standard process on how to store
emails sent by participants containing confidential data.
More attention should be paid to confidentiality, docu-
mentation and costing when using email communication
in order to optimize its use [50].
Discussion
This work has several limitations. Primarily, the literature
review was conducted exclusively using the PubMed li-
brary with generic search terms. Analysis of recruitment
strategies were limited to methods employed by the Medi-
cines Monitoring Unit (MEMO), and authors were unable
to analyse recruitment methods used by the supporting
research networks.
Adherence to allocated treatment is under-reported in
trial publications. This may be due to a concern about
undermining study results. Researchers have attempted
to improve participant adherence with varying success.
However, loss to follow-up continues to be a problem.
Lack of general participant understanding of research
objectives and methodologies may contribute to this.
There still appears to be confusion among both partici-
pants and researchers about when lack of adherence
qualifies as withdrawal from the study or as loss to
follow-up. Further work is necessary in clarifying study
documentation to understand the differences and how
to report these phenomena.
Further research is necessary regarding the now com-
mon use of email correspondence between researchers
and participants. The proclivity to engage in email use in
studies suggests that guidelines on best practices and ef-
forts to secure patient confidentiality should be exam-
ined expeditiously.
Conclusions
The TIME study has successfully recruited more than
21,000 participants over a 2-year period. The recruit-
ment methods used have proven successful and cost-
effective in comparison to similar-sized studies. The
total cost of this major trial is therefore an order of mag-
nitude lower than the cost of a typical commercial
clinic-based study. On the basis of experiences in the
TIME study, as well as comparisons drawn from the lit-
erature, an online methodology and the use of EDC are
viable for conducting clinical research. Numerous strat-
egies should be incorporated to improve recruitment
and optimise the process, and all available strategies
should be used to improve study retention.
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